EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors

Zeynep Eroglu, Timothy Synold, Behnam Badie, An Liu, Arnab Chowdhury, Julie Kilpatrick, Suzette Blanchard, Jana Portnow

Cancer Chemotherapy and Pharmacology · 2024-12 · 94 (6) · 807-813

DOI: 10.1007/s00280-024-04711-2 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 18.10.2024. Verfasst von Zeynep Eroglu und 7 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Therapeutics Research, Duarte, CA, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Furans, Ketones, Microdialysis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: City of Hope.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Eribulin is an inhibitor of microtubule dynamics. It is not as highly protein bound as the taxanes and is less vulnerable to extrusion by P-glycoprotein in the blood–brain barrier (BBB). These features predict that eribulin could play an active role in managing brain tumors. Indeed, the small amount of published clinical data indicates eribulin may have some efficacy against breast cancer brain metastases. To better understand the potential of eribulin for treating brain tumors, we performed an intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in cancer patients undergoing tumor resection.

Methods

After tumor removal, two microdialysis catheters were inserted into peritumoral brain tissue. Approximately 24 h after surgery, a single dose of eribulin 1.4 mg/m 2 was administered intravenously. Dialysate samples were collected continuously for 72 h, with plasma samples collected in parallel. Eribulin concentrations were analyzed by tandem mass spectrometry.

Results

Dialysate samples from 12 intracerebral microdialysis catheters placed in 7 study participants were included in the analysis. A statistically significant difference was observed between eribulin concentrations in brain tissue where BBB was disrupted versus intact, with a difference in mean maximum concentrations on log 2 scale of 3.37 (std err = 0.59, p -value = 0.005). Nonetheless, overall brain to plasma ratios of eribulin only ranged from 0.13 to 1.99%.

Conclusion

Although we could detect higher concentrations of eribulin in brain tissue where BBB was disrupted, intracerebral eribulin levels were not sufficient to predict eribulin would have consistent clinically meaningful activity against tumors in the brain. ClinicalTrials.gov Identifier NCT02338037 (January 9, 2015).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsFuransKetonesMicrodialysisAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic AgentsBlood-Brain BarrierBrainTandem Mass SpectrometryPolyether Polyketides

Stichwörter der Autor:innen

Brain metastasesEribulinGlioblastomaIntracerebral microdialysis

Substanzen

Antineoplastic AgentsFuransKetoneseribulinPolyether Polyketides

Autor:innen und Institutionen

  • City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Therapeutics Research, Duarte, CA, USA.
  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Cancer Biology, Beckman Research Institute of City of Hope, Duarte, CA, USA.
  • Department of Surgery, Division of Neurosurgery, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, CA, USA.

Förderung

  • City of Hope

Zitieren

APA

Eroglu, Z., Synold, T., Badie, B., Liu, A., Chowdhury, A., Kilpatrick, J., Blanchard, S., & Portnow, J. (2024). An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors. Cancer Chemotherapy and Pharmacology, 94(6), 807-813. https://doi.org/10.1007/s00280-024-04711-2

Vancouver

Eroglu Z, Synold T, Badie B, Liu A, Chowdhury A, Kilpatrick J, et al. An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors. Cancer Chemotherapy and Pharmacology. 2024;94(6):807-813. doi:10.1007/s00280-024-04711-2

BibTeX
@article{Eroglu2024,
  author = {Eroglu, Zeynep and Synold, Timothy and Badie, Behnam and Liu, An and Chowdhury, Arnab and Kilpatrick, Julie and Blanchard, Suzette and Portnow, Jana},
  title = {An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  volume = {94},
  number = {6},
  pages = {807--813},
  doi = {10.1007/s00280-024-04711-2}
}
Kostenlos starten →